Mizuho Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh has maintained a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) and increased the price target from $49 to $60.

February 16, 2024 | 11:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho has maintained a Neutral rating on Apellis Pharmaceuticals but raised the price target from $49 to $60.
The increase in price target from $49 to $60 by a reputable analyst suggests a positive outlook on the stock's value, potentially leading to increased investor interest and a short-term price increase. However, the Neutral rating indicates that the analyst sees the stock as fairly valued at its current price, which might temper the impact of the price target increase.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90